Skip to main content


We're creating a new version of this page. See preview

Volume 6 Supplement 6

Beyond the Genome 2012

  • Poster presentation
  • Open Access

Exome sequencing identifies somatic point mutations associated with acquired endocrine resistance in breast cancer cell lines

  • 1, 2,
  • 1, 3,
  • 1, 4,
  • 1, 3,
  • 1, 3, 5,
  • 1, 6,
  • 1, 6,
  • 1, 3, 5,
  • 1, 3,
  • 1, 2 and
  • 1, 3
BMC Proceedings20126 (Suppl 6) :P35

  • Published:


  • Breast Cancer
  • Tamoxifen
  • Endocrine Therapy
  • Human Breast Cancer
  • Breast Cancer Cell Line


Endocrine therapy is an effective treatment of estrogen receptor-positive (ER+) breast tumors, significantly reducing mortality. However, approximately 30% of patients receiving adjuvant endocrine therapy will experience recurrence within a 15-year period. The mechanisms of endocrine resistance are poorly understood. Understanding the underlying genetic diversity of breast cancers responding differently to endocrine therapy is important for the development of more optimal and individualized treatments strategies.

Materials and methods

In the current study, a panel of isogenic MCF-7-derived human breast cancer cell lines [13] that are resistant to tamoxifen only, or to both tamoxifen and fulvestrant, respectively, were analyzed for mutations through exome sequencing and compared with the exome of the parental cell line. In addition, global gene expression levels for the same panel of cell lines were generated. Detected variations were integrated with gene expression profiles and analyzed in the context of prior knowledge of drug action and genes associated with resistance to endocrine therapies as identified by extensive literature curation.

Results and conclusion

A small panel of somatic point mutations potentially associated with acquired endocrine resistance were identified. Future experimental validation will reveal which of the detected mutations that are causatively involved in resistance to endocrine therapy.

Authors’ Affiliations

Sino-Danish Breast Cancer Research Centre, Denmark
Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, Building 208, DK-2800 Kongens Lyngby, Denmark
BGI-Shenzhen, Beishan Industrial Zone, Yantian District, Shenzhen, 518083, China
Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Winslowsvej 25, DK-5000 Odense, Denmark
Department of Human Genetics, Aarhus University, Wilhelm Meyers Allé 4, DK-8000 Aarhus C, Denmark
Section for Pathobiology, Department of Veterinary Disease Biology, Faculty of Life Sciences, University of Copenhagen, Dyrlægevej 88, I. DK-1870 Frederiksberg C, Denmark


  1. Brunner N, Boulay V, Fojo A, Freter CE, Lippman ME, Clarke R: Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes butwithout detectable DNA amplifications. Cancer Res. 1993, 53: 283-290.PubMedGoogle Scholar
  2. Brunner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R: MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res. 1993, 53: 3229-3232.PubMedGoogle Scholar
  3. Brunner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, Frandsen T, Spang-Thomsen M, Fugua SA, Clarke R: MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 1997, 57: 3486-3493.PubMedGoogle Scholar


© Ehlers et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.